Manfred P Lutz
Overview
Explore the profile of Manfred P Lutz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwingel J, Decker M, Schneider L, Sturmer C, Lutz M
Oncol Res Treat
. 2023 May;
46(6):259-267.
PMID: 37166325
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is increasingly common. Screening for pancreatic cancer is not well established but might increase the chance of detection in early...
2.
Sclafani F, Fontana E, Wyrwicz L, Wagner A, Valle J, Smyth E, et al.
Clin Colorectal Cancer
. 2022 May;
21(3):188-197.
PMID: 35637095
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to...
3.
Koessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz M, Obermannova R, et al.
Br J Cancer
. 2021 Aug;
125(7):911-919.
PMID: 34426663
Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual...
4.
Weber D, Decker M, Schuster M, Folz S, Sturmer C, Lutz M
J Cancer Res Clin Oncol
. 2021 Aug;
147(12):3769-3771.
PMID: 34373943
Purpose: We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. It expands...
5.
Maderer A, Fiteni F, Tanis E, Mauer M, Schmitt T, Aust D, et al.
Acta Oncol
. 2021 Aug;
60(11):1543-1547.
PMID: 34355650
No abstract available.
6.
Piiper A, Dikic I, Lutz M, Leser J, Kronenberger B, Elez R, et al.
J Biol Chem
. 2020 Oct;
295(43):14792.
PMID: 33097650
No abstract available.
7.
Schmoll H, Stein A, Van Cutsem E, Price T, Hofheinz R, Nordlinger B, et al.
J Clin Oncol
. 2020 Oct;
39(1):17-29.
PMID: 33001764
Purpose: The PETACC 6 trial investigates whether the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal cancer. Methods: Between November...
8.
Heinrich S, Besselink M, Moehler M, Van Laethem J, Ducreux M, Grimminger P, et al.
BMC Cancer
. 2019 Jul;
19(1):675.
PMID: 31288786
Background: Several new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC), but the support for their use for resectable, borderline resectable and locally advanced PDAC is unclear. Methods:...
9.
Lutz M, Zalcberg J, Ducreux M, Adenis A, Allum W, Aust D, et al.
Eur J Cancer
. 2019 Mar;
112:1-8.
PMID: 30878666
Multimodal primary treatment of localised adenocarcinoma of the stomach, the oesophagus and the oesophagogastric junction (AEG) was reviewed by a multidisciplinary expert panel in a moderated consensus session. Here, we...
10.
Moehler M, Schad A, Maderer A, Atasoy A, Mauer M, Caballero C, et al.
Cancer Chemother Pharmacol
. 2018 Aug;
82(4):733-739.
PMID: 30105460
Purpose: HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metastatic HER2neu+ gastric carcinoma (GC). Lapatinib inhibits both EGFR and HER2neu. We investigated the efficacy and safety of...